Trial Profile

Avatrombopag iN Relapsed or Refractory severe Aplastic Anaemia as EXtra Therapy a Bayesian Optimal Phase II study

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avatrombopag (Primary)
Indications Aplastic anaemia
Focus Adverse reactions; Therapeutic Use
Acronyms The DIAAMOND-Ava NEXT Trial

Most Recent Events

13 Dec 2022 Results (n=14) assessing Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Nave and Relapsed/Refractory Severe Aplastic Anaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition
24 Jul 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com